Zhejiang Cancer Hospital
Clinical trials sponsored by Zhejiang Cancer Hospital, explained in plain language.
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New cocktail of chemo and immunotherapy takes on pancreatic cancer
Disease control Recruiting nowThis Phase 3 trial tests whether a sequence of chemotherapy drugs (AG followed by mFOLFOX) plus two immunotherapy agents (serplulimab and bevacizumab) works better than standard AG chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. Ab…
Phase: PHASE3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New combo aims to tame MALT lymphoma with less radiation damage
Disease control Recruiting nowThis phase 2 trial is testing a new approach for adults with early-stage (I-II) MALT lymphoma, a slow-growing cancer. Participants first receive a very low dose of radiation (4 Gy total) over two days, then take a daily targeted drug called orelabrutinib for up to 6 months. The g…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
New hope for breast cancer spread to liver: targeted chemo trial opens
Disease control Recruiting nowThis study tests a new way to give chemotherapy for breast cancer that has spread to the liver and stopped responding to standard treatments. The drugs are delivered directly into the liver artery to target tumors while reducing side effects. About 30 adults aged 18-70 with liver…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New hope for hard-to-treat ovarian cancer: targeted drug combo enters trial
Disease control Recruiting nowThis study tests a new drug called distamab vedotin (RC48) combined with carboplatin for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combination works better and causes fewer side effects than standard chemotherapy. Abou…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New hope for HER2+ breast cancer: switching drug combos after treatment fails
Disease control Recruiting nowThis study looks at what happens when people with HER2-positive advanced breast cancer switch between two different targeted therapy combinations after their first treatment stops working. About 600 women will be split into two groups: one switches from HP+chemo to HPy+chemo, the…
Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
New hope for tough breast cancer: drug cocktail trial launches
Disease control Recruiting nowThis study tests whether adding two drugs (entinostat and anlotinib) to a standard hormone therapy (fulvestrant) can shrink tumors or slow cancer growth in people with a common type of advanced breast cancer (HR+/HER2-). About 118 adults whose cancer returned or worsened after pr…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Cord blood infusion aims to rescue cancer Patients' platelet counts
Disease control Recruiting nowThis study tests whether a single infusion of umbilical cord blood can safely raise platelet levels in cancer patients whose platelets have dropped due to chemotherapy or other cancer treatments. Researchers will enroll 25 people aged 12 to 65 and monitor their blood counts for 2…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New drug combo aims to wipe out stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding the experimental drug IBI363 to standard chemotherapy can better shrink or eliminate stomach or gastroesophageal junction cancer before surgery. It includes 60 adults aged 18-75 whose tumors lack a certain immune marker (MHC-II negative). The main …
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New hope for brain cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) for people with a type of brain lymphoma that has come back or is hard to treat. The goal is to see if this mix can shrink tumors and help patients live longer. About 24 adults will take part,…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Glow-in-the-Dark injection could help surgeons spot hidden cancer
Diagnosis Recruiting nowThis study tests an injectable imaging agent called NC527-X that makes tumors glow during surgery, helping surgeons see and remove them more precisely. About 400 adults with solid tumors who are scheduled for surgery will receive the injection before their operation. The main goa…
Phase: PHASE1 • Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 01, 2026 18:01 UTC
-
Ginseng's hidden effects revealed in new study
Knowledge-focused Recruiting nowThis study looks at how taking American ginseng for two weeks changes the chemicals in urine and blood of healthy adults. Twenty people aged 18 to 45 will take 3 grams of ginseng powder daily. Researchers will use advanced lab tests to track metabolic changes and monitor for any …
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 23, 2026 22:01 UTC
-
Real-world study examines breast cancer drug's effectiveness outside clinical trials
Knowledge-focused Recruiting nowThis study will review medical records of 200 patients in China with HER2-negative metastatic breast cancer who received sacituzumab govitecan. Researchers want to see how long the drug keeps cancer from growing and how well patients tolerate it. The goal is to understand real-wo…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:54 UTC
-
CT scans reveal how breathing tubes fit inside patients
Knowledge-focused Recruiting nowThis study uses CT scans to see how three different breathing tubes (laryngeal masks) sit in the throat of patients under general anesthesia. Researchers want to understand which device fits best and causes the least tissue pressure. Nine adults scheduled for CT-guided procedures…
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:55 UTC
-
Swallow study seeks safer airway devices
Knowledge-focused Recruiting nowThis study watches how normal throat structures move during a barium swallow test in people already having a routine barium meal exam. The goal is to learn more about these movements to help design better laryngeal masks, which are devices used to help patients breathe during med…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:06 UTC